8-K current report · filed Nov 19, 2026

Edwards Lifesciences (EW) 8-K Current Report: November 19, 2026

Item 1.01Item 2.03EW overview

Short answer

Edwards Lifesciences (EW) filed an 8-K current report with the SEC on November 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Edwards entered an amended and restated five-year credit agreement on November 19, 2026.

Edwards Lifesciences 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Edwards entered an amended and restated five-year credit agreement on November 19, 2026
  • Facility refresh replaces the July 15, 2022 credit agreement
  • Improved terms and extended maturity strengthen liquidity flexibility and refinancing runway
  • Borrowers include Edwards and certain subsidiaries, with Bank of America as administrative agent

Item 2.03 · Creation of a Direct Financial Obligation

  • New five-year $750 million multi-currency unsecured revolving facility replaces 2022 credit agreement
  • Maturity extended to November 19, 2031, supporting liquidity and general corporate purposes
  • Borrowing costs tied to SOFR or base rate plus leverage-based or debt-rating margin
  • Capacity expandable by up to $375 million, subject to lender approval and conditions
  • No borrowings outstanding at filing date, limiting immediate balance-sheet impact

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Edwards Lifesciences 8-K filings

Get the next EW 8-K as it lands

Follow EW for push alerts, or ask the research agent what this filing means.